A favorable trend with P-CAB in moderate–to–severe exacerbations was observed in patients with a lower comorbidity burden (CCI ≤ 1), with this pattern being more pronounced for severe exacerbations.
← all excerpts
Comparative risk of pneumonia and acute exacerbation between P-CAB and PPI use in patients with COPD and GERD.
1
—
—